Loading...
XSTONANEXA
Market cap28mUSD
Dec 23, Last price  
2.32SEK
1D
-7.57%
1Q
45.91%
Jan 2017
-70.17%
IPO
-74.31%
Name

Nanexa AB

Chart & Performance

D1W1MN
XSTO:NANEXA chart
P/E
—
P/S
10.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
41.69%
Rev. gr., 5y
147.02%
Revenues
29m
+925.42%
1,481,000658,695280,000105,000318,8401,710,0002,367,0002,374,0002,860,00029,327,000
Net income
-76m
L+30.44%
-928,356-4,126,061-6,348,708-7,970,570-11,168,634-12,950,000-21,736,000-35,999,000-58,571,000-76,398,000
CFO
-43m
L+441.96%
563,994-3,293,259-6,405,349-5,072,358-6,756,523-9,417,000-16,827,000-25,128,000-7,871,000-42,658,000
Earnings
Feb 19, 2025

Profile

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
URL
https://nanexa.com/
IPO date
Jun 17, 2015
Employees
21
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
29,327
925.42%
2,860
20.47%
2,374
0.30%
Cost of revenue
(20,758)
23,227
27,604
Unusual Expense (Income)
NOPBT
50,085
(20,367)
(25,230)
NOPBT Margin
170.78%
Operating Taxes
(112)
(64)
(8)
Tax Rate
NOPAT
50,197
(20,303)
(25,222)
Net income
(76,398)
30.44%
(58,571)
62.70%
(35,999)
65.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
75,387
17,515
164,324
BB yield
-87.37%
-12.47%
-115.29%
Debt
Debt current
1,945
2,204
1,259
Long-term debt
2,087
4,068
2,573
Deferred revenue
Other long-term liabilities
3,766
18,220
(2,573)
Net debt
(61,137)
(74,912)
(101,860)
Cash flow
Cash from operating activities
(42,658)
(7,871)
(25,128)
CAPEX
(1,979)
(35,422)
(25,789)
Cash from investing activities
(34,248)
(35,422)
(25,789)
Cash from financing activities
60,892
18,814
143,886
FCF
51,045
(25,680)
(31,376)
Balance
Cash
65,168
81,182
105,660
Long term investments
1,000
2
32
Excess cash
63,703
81,041
105,573
Stockholders' equity
(222,131)
(155,440)
(98,163)
Invested Capital
325,759
288,520
252,838
ROIC
16.34%
ROCE
48.33%
EV
Common stock shares outstanding
70,148
50,696
35,633
Price
1.23
-55.60%
2.77
-30.75%
4.00
-63.74%
Market cap
86,282
-38.56%
140,427
-1.48%
142,534
-39.60%
EV
25,145
65,515
40,674
EBITDA
55,317
(9,863)
(22,327)
EV/EBITDA
0.45
Interest
487
666
186
Interest/NOPBT
0.97%